share_log

LadRx (NASDAQ:CYTR) Coverage Initiated by Analysts at StockNews.com

Defense World ·  Jan 8, 2023 03:31

Analysts at StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report issued on Sunday. The firm set a "hold" rating on the stock.

LadRx Price Performance

LadRx has a twelve month low of $0.05 and a twelve month high of $0.86. The firm has a 50-day moving average of $0.10 and a 200 day moving average of $0.12.

Get LadRx alerts:

About LadRx

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.

Further Reading

  • Get a free copy of the StockNews.com research report on LadRx (CYTR)
  • MarketBeat: Week in Review 01/02-01/06
  • Why is the CrowdStrike Stock Price Struggling?
  • Four Undervalued Healthcare Stocks for 2023
  • WWE Stock: Vince McMahon Wants Back In The Show
  • NVIDIA Is Bottoming But Don't Buy It Just Yet

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment